New liposomal drug combo aims to boost lymphoma remission

NCT ID NCT06594640

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of drugs for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The experimental drug is a liposomal form of mitoxantrone, given with standard chemotherapy and rituximab. The trial has two parts: first, finding the safest dose, then checking how well it works. About 108 adults with untreated DLBCL will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, prednisone, and rituximab
What this could lead to: If successful, this could offer a more effective and possibly safer first-line treatment for diffuse large B-cell lymphoma, improving remission rates.
What could go wrong: This is an early-phase trial (phase I/II) with only 108 participants, so results may not apply broadly. The new drug combination may cause unexpected side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Institute of Hematology & Blood Disease Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.